Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
J Immunol. 2013 Aug 15;191(4):2009-17. doi: 10.4049/jimmunol.1301317. Epub 2013 Jul 12.
Immune cells comprise a substantial proportion of the tumor mass in human nonsmall cell lung cancers (NSCLC), but the precise composition and significance of this infiltration are unclear. In this study, we examined immune complexity of human NSCLC as well as NSCLC developing in CC10-TAg transgenic mice, and revealed that CD4(+) T lymphocytes represent the dominant population of CD45(+) immune cells, and, relative to normal lung tissue, CD4(+)Foxp3(+) regulatory T cells (Tregs) were significantly increased as a proportion of total CD4(+) cells. To assess the functional significance of increased Tregs, we evaluated CD8(+) T cell-deficient/CC10-TAg mice and revealed that CD8(+) T cells significantly controlled tumor growth with antitumor activity that was partially repressed by Tregs. However, whereas treatment with anti-CD25-depleting mAb as monotherapy preferentially depleted Tregs and improved CD8(+) T cell-mediated control of tumor progression during early tumor development, similar monotherapy was ineffective at later stages. Because mice bearing early NSCLC treated with anti-CD25 mAb exhibited increased tumor cell death associated with infiltration by CD8(+) T cells expressing elevated levels of granzyme A, granzyme B, perforin, and IFN-γ, we therefore evaluated carboplatin combination therapy resulting in a significantly extended survival beyond that observed with chemotherapy alone, indicating that Treg depletion in combination with cytotoxic therapy may be beneficial as a treatment strategy for advanced NSCLC.
免疫细胞构成了人类非小细胞肺癌(NSCLC)肿瘤块的很大一部分,但这种浸润的确切组成和意义尚不清楚。在这项研究中,我们研究了人类 NSCLC 以及 CC10-TAg 转基因小鼠中发生的 NSCLC 的免疫复杂性,并揭示 CD4(+)T 淋巴细胞是 CD45(+)免疫细胞的主要群体,与正常肺组织相比,CD4(+)Foxp3(+)调节性 T 细胞(Tregs)作为总 CD4(+)细胞的比例显著增加。为了评估 Tregs 增加的功能意义,我们评估了 CD8(+)T 细胞缺陷/CC10-TAg 小鼠,并揭示 CD8(+)T 细胞显著控制肿瘤生长,具有抗肿瘤活性,而 Tregs 部分抑制了这种活性。然而,虽然用抗 CD25 耗竭 mAb 作为单一疗法优先耗尽 Tregs 并改善 CD8(+)T 细胞介导的肿瘤进展控制,但在后期阶段,类似的单一疗法无效。由于用抗 CD25 mAb 治疗的患有早期 NSCLC 的小鼠表现出与浸润相关的肿瘤细胞死亡,浸润的 CD8(+)T 细胞表达高水平的 granzyme A、granzyme B、穿孔素和 IFN-γ,因此我们评估了卡铂联合治疗,导致与单独化疗相比生存时间显著延长,表明 Treg 耗竭联合细胞毒性治疗可能是晚期 NSCLC 的一种有益治疗策略。